ESC Congress 2024 Lipidology Preview, with Professor Kausik Ray

Boasting 12 Hot Line sessions, 26 late-breaking science sessions, 38 late-breaking trials, and more than 230 other sessions, the European Society of Cardiology (ESC) Congress 2024 has the potential to be 1 of the most influential cardiology meetings in recent memory.

With the meeting headlined by anticipated data releases from FINEARTS-HF, OCEANIC-AF, and other phase 3 clinical trials, tens of thousands of cardiologists and other care providers with an interest in metabolic health are expected to descend upon London for the annual meeting, which is scheduled for August 30 to September 2, 2024.

In anticipation of the meeting, HCPLive Cardiology reached out to leading subject matter experts to learn what they were most looking forward to from ESC Congress 2024, including Kausik Ray, MD, professor of Public Heath, director of the Imperial Centre for CVD Prevention, deputy director of Imperial Clinical Trials Unit and head of Commercial Trials at Imperial College London. In the video featured above, Ray gives our editorial team and audience members a look behind the curtain at what he is looking forward to most and why from the more than 2000 abstracts set to be presented at the meeting.

In the discussion, Ray calls attention to new data for plozasiran in familial chylomicronemia syndrome being presented by Gerald Watts, MD, PhD, on September 2, the SENIOR RITA trial being presented in Hot Line 8 by Vijay Kunadian, MD, on September 1, and a host of different studies examining failed implementation of newer therapies, both pharmacological and surgical techniques.

For those interested in work led or presented by Ray during the meeting, check out our list of his sessions (excluding industry-sponsored symposia) below.

Sessions (in chronological order):

• Revolutionary new cardiovascular disease therapies: future now
• Role: Presenter - Monoclonal antibodies, gene silencing, and gene editing (CRISPR) therapies for the treatment of hyperlipidaemia
  Time: August 31, 2024 from 13:45 to 15:00 BST

• Cardiovascular disease management in the UK versus other European countries
• Role: Presenter - Lipid guidelines: comparison between National Institute for Health and Care Excellence (NICE) and ESC guidance
  Time: September 1, 2024 from 08:15 to 09:45 BST

• Registries, observational, and other studies on lipids
• Role: Chairperson & Presenter - A global perspective of Lp(a) levels in patients with coronary heart disease - Implications for risk factor control & future trials from the INTERASPIRE Study
  Time: September 1, 2024 from 13:45 to 15:00 BST

• Great Debate: 'fire and forget' beats personalised lipid-lowering treatment
• Role: Presenter - Fire and forget' beats personalised lipid-lowering treatment: Pro
  Time: September 1, 2024 from 17:30 to 18:30 BST

Relevant disclosures for Ray include AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Esperion Therapeutics, Novartis, NewAmsterdam, Novo Nordisk, and others.

References:

1. European Society of Cardiology. Welcome to ESC Congress 2024! YouTube. August 21, 2024. Accessed August 27, 2024. https://www.youtube.com/watch?v=BDikGjNXauY&t=4s.